137 related articles for article (PubMed ID: 23220283)
21. Identification of novel PTPRQ phosphatase inhibitors based on the virtual screening with docking simulations.
Park H; Yu KR; Ku B; Kim BY; Kim SJ
Theor Biol Med Model; 2013 Aug; 10():49. PubMed ID: 23981594
[TBL] [Abstract][Full Text] [Related]
22. Discovery of MEK/PI3K dual inhibitor via structure-based virtual screening.
Park H; Lee S; Hong S
Bioorg Med Chem Lett; 2012 Aug; 22(15):4946-50. PubMed ID: 22771009
[TBL] [Abstract][Full Text] [Related]
23. Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening.
Choi H; Lee Y; Park H; Oh DS
Bioorg Med Chem Lett; 2010 Nov; 20(21):6195-8. PubMed ID: 20850306
[TBL] [Abstract][Full Text] [Related]
24. Actin filaments-stabilizing and -bundling activities of cofilin-phosphatase Slingshot-1.
Kurita S; Gunji E; Ohashi K; Mizuno K
Genes Cells; 2007 May; 12(5):663-76. PubMed ID: 17535256
[TBL] [Abstract][Full Text] [Related]
25. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel inhibitors of mitogen-activated protein kinase phosphatase-1 with structure-based virtual screening.
Park H; Jeon JY; Kim SY; Jeong DG; Ryu SE
J Comput Aided Mol Des; 2011 May; 25(5):469-75. PubMed ID: 21567231
[TBL] [Abstract][Full Text] [Related]
27. IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.
Nagarajan S; Doddareddy Mr; Choo H; Cho YS; Oh KS; Lee BH; Pae AN
Bioorg Med Chem; 2009 Apr; 17(7):2759-66. PubMed ID: 19285872
[TBL] [Abstract][Full Text] [Related]
28. Discovery of protein phosphatase 2C inhibitors by virtual screening.
Rogers JP; Beuscher AE; Flajolet M; McAvoy T; Nairn AC; Olson AJ; Greengard P
J Med Chem; 2006 Mar; 49(5):1658-67. PubMed ID: 16509582
[TBL] [Abstract][Full Text] [Related]
29. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
Park H; Bahn YJ; Ryu SE
Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
[TBL] [Abstract][Full Text] [Related]
30. Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology model.
Li S; Zhou Y; Lu W; Zhong Y; Song W; Liu K; Huang J; Zhao Z; Xu Y; Liu X; Li H
J Chem Inf Model; 2011 Nov; 51(11):2939-47. PubMed ID: 21995341
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking.
Ren JX; Cheng Z; Huang YX; Zhao JF; Guo P; Zou ZM; Xie Y
Biomed Pharmacother; 2017 May; 89():376-385. PubMed ID: 28249240
[TBL] [Abstract][Full Text] [Related]
32. Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of Leptospira spp.: homology modeling, docking, and molecular dynamics study.
Pradhan D; Priyadarshini V; Munikumar M; Swargam S; Umamaheswari A; Bitla A
J Biomol Struct Dyn; 2014; 32(2):171-85. PubMed ID: 23383626
[TBL] [Abstract][Full Text] [Related]
33. Phoslactomycin targets cysteine-269 of the protein phosphatase 2A catalytic subunit in cells.
Teruya T; Simizu S; Kanoh N; Osada H
FEBS Lett; 2005 Apr; 579(11):2463-8. PubMed ID: 15848189
[TBL] [Abstract][Full Text] [Related]
34. Two-track virtual screening approach to identify both competitive and allosteric inhibitors of human small C-terminal domain phosphatase 1.
Park H; Lee HS; Ku B; Lee SR; Kim SJ
J Comput Aided Mol Des; 2017 Aug; 31(8):743-753. PubMed ID: 28653253
[TBL] [Abstract][Full Text] [Related]
35. Structure-based virtual screening approach to the discovery of novel inhibitors of factor-inhibiting HIF-1: identification of new chelating groups for the active-site ferrous ion.
Ko S; Lee MK; Shin D; Park H
Bioorg Med Chem; 2009 Nov; 17(22):7769-74. PubMed ID: 19822432
[TBL] [Abstract][Full Text] [Related]
36. Identification of purple acid phosphatase inhibitors by fragment-based screening: promising new leads for osteoporosis therapeutics.
Feder D; Hussein WM; Clayton DJ; Kan MW; Schenk G; McGeary RP; Guddat LW
Chem Biol Drug Des; 2012 Nov; 80(5):665-74. PubMed ID: 22943065
[TBL] [Abstract][Full Text] [Related]
37. A potent and selective inhibitor for the UBLCP1 proteasome phosphatase.
He Y; Guo X; Yu ZH; Wu L; Gunawan AM; Zhang Y; Dixon JE; Zhang ZY
Bioorg Med Chem; 2015 Jun; 23(12):2798-809. PubMed ID: 25907364
[TBL] [Abstract][Full Text] [Related]
38. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
39. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.
Park H; Jeong Y; Hong S
Bioorg Med Chem Lett; 2012 Jan; 22(2):1027-30. PubMed ID: 22196123
[TBL] [Abstract][Full Text] [Related]
40. In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
Rao GS; Ramachandran MV; Bajaj JS
J Biomol Struct Dyn; 2006 Feb; 23(4):377-84. PubMed ID: 16363874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
